Alnylam Pharmaceuticals, Inc.
Pharmaceutical firm reports on IPO, financial results
Published in Healthcare Finance, Tax and Law Weekly, September 1st, 2004
Alnylam is focused on creating a significant and sustainable product pipeline using RNAi to silence genes that are implicated in the cause or pathway of human disease.
The company's business strategy is focused on leveraging its scientific leadership and intellectual property strength through creating significant partnerships with esteemed companies in the industry including Merck, Isis Pharmaceuticals and others. Alnylam's initial public offering took place in May 2004.
"In the second quarter we continued our...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Advanced Viral Research Corp.
Third installment of $3 million dollars received for shares of biopolymer stock - Advancis Pharmaceutical Corp.
Pharmaceutical company reports loss of $0.37 per share - Aksys, Ltd.
Hemodialysis firm reports loss of $0.22 per share for second quarter - Alpharma, Inc.
Pharmaceutical firm reports 5% decrease in revenues - Ambri Limited
Australian biotech firm reduces annual cash expenditure by 41% - Amylin Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.42 per share - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
